Prognostic Value of Hematological Parameters in Locally Advanced Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy

• DOI: 10.21873/anticanres.13973
• Publication Date: 2019-12-31T20:55:12Z
• Authors: HYUN JUNG LEE; JONG MI KIM; YOO JEONG CHIN; GUN OH CHONG; SHIN-HYUNG PARK; YOON HEE LEE; DAE GY HONG; YOON SOON LEE
• Keywords: Neutrophils; Uterine Cervical Neoplasms; Chemoradiotherapy; Middle Aged; Prognosis; Disease-Free Survival; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Multivariate Analysis; Humans; Female; Lymphocytes; Neoplasm Recurrence, Local; Neoplasm Staging

We evaluated the clinical implications of pre- and post-treatment hematological parameters as prognostic factors in patients with locally advanced cervical cancer (LACC) who received definitive concurrent chemoradiotherapy (CCRT).We retrospectively analyzed 125 patients with LACC (FIGO stage IIB to IIIB) who received definitive CCRT. Clinical factors and hematological parameters, including neutrophil-to-lymphocyte ratio (NLR) were assessed pre- and post-CCRT. Univariate and multivariate analysis for disease-free survival (DFS) and overall survival (OS) were performed using clinicopathological and hematological parameters.Disease recurred in 46 (36.8%) patients, and 24 patients (19.2%) died. On multivariate analysis, post-treatment NLR, ΔNLR (pre-treatment NLR/post-treatment NLR) and ΔPLR (platelet-to-lymphocyte ratio) (pretreatment PLR/post-treatment PLR) were significant prognostic factors for DFS, and only post-treatment NLR was a significant prognostic factor for OS (p<0.001). However, pre-treatment hematological parameters were not associated with prognosis.Post-treatment hematological parameters, particularly NLR, may serve as a prognostic indicator in patients with LACC who received definitive CCRT.